Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Should You Sell?

Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped down prior to trading on Tuesday . The stock had previously closed at $9.87, but opened at $9.5101. Sysmex shares last traded at $9.83, with a volume of 109,974 shares traded.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group upgraded shares of Sysmex from a “hold” rating to a “buy” rating in a research note on Thursday, October 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Sysmex currently has a consensus rating of “Moderate Buy”.

Sysmex Stock Performance

The business’s fifty day moving average is $10.18 and its 200-day moving average is $12.97. The company has a quick ratio of 2.49, a current ratio of 3.34 and a debt-to-equity ratio of 0.11. The company has a market cap of $6.18 billion, a PE ratio of 19.63 and a beta of 1.17.

Sysmex (OTCMKTS:SSMXY) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.16 earnings per share for the quarter, hitting the consensus estimate of $0.16. Sysmex had a net margin of 9.32% and a return on equity of 9.86%. The business had revenue of $826.60 million for the quarter, compared to the consensus estimate of $880.80 million. As a group, research analysts predict that Sysmex Corporation ADR will post 0.57 EPS for the current fiscal year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.